Overview

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the effect of mitapivat versus placebo on anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
Phase:
Phase 3
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.